DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Precision Medicine Market (2018-2023)" report has been added to ResearchAndMarkets.com's offering.
The Asia-Pacific precision medicine market is projected to grow at a compound annual growth rate (CAGR) of 16.63%, leading to a revenue of USD 20.9 billion by 2023.
Asia-Pacific is the fastest growing precision medicine market in the world. Major countries like China, India and Japan are adopting healthcare technologies at a rapid pace, resulting in improvements in the treatments and solutions for uncommon diseases. This is why the demand for precision medicine is also increasing.
The market is expected to expand in the region because of advancements in recent research which are helping in the diagnosis of diseases, its appropriate risks and optimal therapy.
China is dominating the precision medicine market due to its ageing population and rise in the rate of chronic diseases. India is experiencing the fastest growth in the Asia-Pacific region. Rising investments in research and development have also triggered the growth of the precision medicine market.
Diagnostic tool companies are expected to exhibit the highest growth rate in the region due to increased investments in research and technology, and clinical trials in the region. The cancer therapeutics segment is expected to register the highest growth rate during the forecasted period 2018-2023 due to higher incidence of cancer.
Chapter 1: Executive Summary
Chapter 2: Asia-Pacific Precision Medicine Market - Overview
Chapter 3: Asia-Pacific Precision Medicine Market - by Countries
Chapter 4: Competitive Landscape
Chapter 5: Conclusion
- Abbott Laboratories
- GE Healthcare
- GlaxoSmithKline (GSK)
- Johnson & Johnson
- Randox Laboratories
- Almac Group
- Novartis AG
- Teva Pharmaceuticals Limited
- Quest Diagnostics
For more information about this report visit https://www.researchandmarkets.com/research/2rcm4w/asiapacific?w=4